Age | Sex | TNM classification | Initial Stage | TKI | Surgical procedure | Pathological outcome | Complication | Outcome | |
---|---|---|---|---|---|---|---|---|---|
Takamochi et al. 2007 [5] | 73 | F | cT2N2M1 | IV | gefitinib | bilobectomy | pT1N0M1 | no recurrence (2 months) | |
57 | F | cT1N2M0 | IIIA | gefitinib | lobectomy | CR | chylothorax | no recurrence (1.5 months) | |
Kappers et al. 2008 [6] | 67 | F | IIIA | erlotinib | lobectomy | near CR | unknown | ||
Levchenko EV et al. 2009 [7] | 62 | F | IV | erlotinib | bilobectomy | EF 1a | meta in thorax (15 months) | ||
48 | M | IV | gefitinib | lobectomy | residual viable tumor | adrenal meta (5 months), DWD (8 months) | |||
Shen et al. 2010 [9] | 73 | F | cT2N3M0 | IIIB | gefitinib | lobectomy | alveolar cell carcinoma, N0 | no recurrence (20 months) | |
Hishida et al. 2010 [8] | 73 | F | cT4N2M0 | IIIB | gefitinib | lobectomy | pT2N1M0 | bone meta (6 months), DWD (17 months) | |
63 | F | cT2N3M1 | IV | gefitinib | lobectomy | pT1N2M0 | brain meta (5 months), AWD (24 months) | ||
33 | F | cT4N0M0 | IIIA | gefitinib | extra pleural pneumonectomy | pT4N2M0 | brain meta (3 months), DWD (19 months) | ||
54 | M | cT4N3M1 | IV | gefitinib | lobectomy | pT4N0M0 | meta in thorax (6 months), AWD (10 months) | ||
71 | F | cT2N3M0 | IIIB | gefitinib | lobectomy | pT2N2M0 | meta in thorax (4 months), DWD (21 months) | ||
57 | F | cT4N0M1 | IV | gefitinib | lobectomy | pT2N0M0 | unknown | ||
Liu et al. 2011 [10] | 64 | F | cT2bN2M1 | IV | gefitinib | bilobectomy | CR | no recurrence (21 months) Hashimoto et | |
Hashimoto et al. 2012 [12] | 66 | F | cT4N1M1a | IV | gefitinib | lobectomy | pT2aN0M0 StageIB | no recurrence (12 months) | |
Ong et al. 2012 [11] | 78 | F | cT3N2M0 | IIIA | erlotinib | lobectomy | residual viable tumor, N0 | meta in thorax (10 months) | |
Funakoshi et al. 2012 [14] | 69 | F | cT2aN0M0 | IB | gefitinib | pneumonectomy | pT2aN0M0 StageIB | empysma | no recurrence (26 months) |
Marech et al. 2013 [13] | 67 | F | cT4N2M0 | IIIB | gefitinib | lobectomy | pT1N0M0 | no recurrence (7 months) | |
Lopez-Gonzales et al. 2013 [15] | 66 | F | cT4N2M0 | IIIB | gefitinib | pneumonectomy | <10% of residual viable tumor | brain meta (17 months), AWD (22 months) | |
Hishida et al. 2014 [4] | 62 | F | cT2aN2M0 | IIIA | gefitinib | lobectomy | EF 1a | no recurrence (36 months) | |
51 | F | cT2N3M1 | IV | gefitinib | lobectomy | pT1N0M0, EF0 | brain meta (2 months), AWD (94 months) | ||
58 | F | cT1bN0M1a | IV | gefitinib | bilobectomy | pT1N1M0, EF1a | meta in thorax (14.4 months), AWD (63 months) | ||
58 | F | cT2N2M0 | IIIA | gefitinib | pneumonectomy | CR | brain meta (28 months), DWD (68 months) | ||
Our two cases. 2017 | 72 | F | cT2N2M0 | IIIA | gefitinib | lobectomy | pT1N2M0, EF 1b | brain meta (8 months), DWD (18 months) | |
68 | F | cT3N2M0 | IIIA | afatinib | bilobectomy | pT1N0M0, EF 2a | bone meta (8 months), AWD (14 months) |